26 North Street,

Boston,

MA,

US,

ZIP: 02109

Phone: +16174554188

There aren’t many targets like BCMA - well validated, preferentially expressed by mature B lymphocytes and specific to multiple myeloma – meaning that novel drugs against BCMA continue to emerge. This brings with it an unmatched therapeutic and commercial opportunity for multiple myeloma patients, a large proportion of whom continue to experience poor tolerability, duration of response and develop resistance.

As such, the BCMA Targeted Therapies Summit returns for its second year, as the industry’s definitive conference dedicated to:

- Exploring and differentiating the next-generation drug modalities targeting BCMA, including bispecific antibody constructs, antibody–drug conjugates, and chimeric antigen receptor (CAR)-modified T-cell therapy

- Rationalizing combination approaches and crack the sequencing conundrum to overcome resistance mechanisms

- Sharing toxicology and safety data to optimize drug potency and balancing dose-response relationships, particularly when it comes to combination strategies

- Investigating multiple myeloma biology and quantify BCMA using optimized preclinical models and assays to accelerate translation of preclinical assets into the clinic

Following the recent FDA approval of Cilta-Cel from Janssen Pharmaceutical Companies of Johnson & Johnson & Legend Biotech Corporation in Relapsed/Refractory Multiple Myeloma, marking J&J’s first cell therapy approval, the space is set to expect many more & there is truly nowhere better to unite with this exploding community and progress your drug development than at this exclusive ‘gathering of minds’.

Tickets    https://go.evvnt.com/1093163-2?pid=1052
Brochure https://go.evvnt.com/1093163-3?pid=1052

Prices:
Drug Developer - Conference Only USD 2999.00
Drug Developer - Conference + 1 Workshop USD 3648.00
Drug Developer - Conference + 2 Workshops USD 4297.00
Academic - Conference Only USD 2599.00
Academic - Conference + 1 Workshop USD 3148.00
Academic - Conference + 2 Workshops USD 3697.00
Service Provider - Conference Only USD 3599.00
Service Provider - Conference + 1 Workshop USD 4348.00
Service Provider - Conference + 2 Workshops USD 5097.00

Category: Conferences | Science, Health & Medicine | Pharmaceuticals

Eric Fedyk, Global Program Leader of BCMA Asset 2seventybio, Enrique Zudaire, Director - Scientific, Immune Oncology Translational Research, Johnson & Johnson Services, David DiLillo, Director, Immuno- Oncology Regeneron, Hong Ma, Senior Vice President, Clinical Development CARsgen Therapeutics, Mike Damore, Director & Lead - Translational Oncology Pfizer, Marc-Steffen, Raab Professor of Medicine Heidelberg University, Shambavi Richard, Assistant Professor of Medicine (Hematology and Medical Oncology) Mount Sinai Medical Center, Shinta Cheng, Vice President, Clinical Development SpringWorks, Philip McCarthy, Director & Professor - Oncology & Internal Medicine, Transplant, Cellular Therapy Center & Medicine Roswell Park Cancer Institute, Damian Green, Associate Professor - Clinical Research Division Fred Hutchinson Cancer Research Center (FHCRC), Christopher Heery, Chief Medical Officer, Arcellx, Cesar Sommer, Senior Director, Allogene Therapeutics, Hans Chulhee Lee, Assistant Professor, MD Anderson Cancer Center, Suzette Girgis, Senior Director & Head of Clinical Pharmacology & Hematologic Malignancies Johnson & Johnson Services, Martina Sersch, Chief Medical Officer, Gracell Bio, Nathan Martin, Translational Scientist & Project Lead Bristol Myers Squibb, Nizar Bahlis, Associate Professor - Hematology & Oncology University of Calgary, Dexiu Bu Senior Principle Scientist, CART group, Immuno-Oncology & Hematology Novartis Institute for Biomedical Research, Faiza Zafar, Senior Medical Science Liaison, Legend Biotech, Andreas Pahl, CSO & Executive Vice President Heidelberg Pharma Research GmbH, Brandon Kremer, Group Senior Medical Director, Clinical Development Lead GlaxoSmithKline, Chetasi Talati, Medical Director, AbbVie, Maria-Victoria Mateos, Consultant Physician, Myeloma Program & Clinical Trials Unit. Haematology Department & Associate Professor of Medicine University of Salamanca